文献速递神经肿瘤

脑膜瘤复发风险估计在观察性队列中的变异:日历时间、WHO分类、地理环境与医疗体系的影响

Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systems.
PubMed 文献 · J Neurooncol · 2026-08-28

该研究分析15国31中心4111例原发WHO 1/2级脑膜瘤患者(1990-2019),采用逆概率删失加权回归标准化估计5年和10年复发风险。结果显示复发风险估计随时间、医疗体系和地理环境变化,较近期日历期预测复发风险更高,尤其WHO 2级5年(≥2013 vs ≤2007:RR 1.60,95%CI 1.19-2.01),而WHO分类版本间(2007 vs 2016)大致相当。结论认为复发风险估计不稳定,受数据积累模式影响,对回顾性标本分子分类器和历史基准临床试验有重要启示。

要点

  • 脑膜瘤复发风险估计随日历时间、医疗体系和地理环境变化,非稳定常数。
  • 较近期日历期预测复发风险更高,WHO 2级5年风险比达1.60(95%CI 1.19-2.01)。
  • WHO分类版本(2007 vs 2016)间复发风险估计大致相当。

核心结论

  • 脑膜瘤复发风险估计随时间与设置变化,受数据积累模式影响,复发事件与检测历史背景锁定。

研究设计与样本

  • 分析15国31中心4111例原发WHO 1/2级脑膜瘤患者(1990-2019),采用逆概率删失加权回归标准化估计5年和10年复发风险,调整临床、手术和病理变量。

主要发现

  • 较近期日历期与更高预测复发风险相关,尤其WHO 2级5年(≥2013 vs ≤2007:RR 1.60,95%CI 1.19-2.01)。
  • 调整后不同医疗体系和地理环境间仍观察到复发风险估计差异。
  • WHO分类版本(2007 vs 2016)间复发风险估计大致相当。
  • 队列层面可视化显示随访时长、纳入模式和复发检测存在显著异质性。

临床怎么用

  • 解读脑膜瘤复发风险时需考虑日历时间、地理和医疗体系背景,避免直接套用历史基准。
  • 利用回顾性标本开发分子分类器或依赖历史基准的临床试验应认识复发风险估计的不稳定性。
  • 建议透明可视化观察性队列组成和个体事件时间以提高可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recurrence risk estimates underpin meningioma research, including molecular classification and clinical trial benchmarking, yet are often based on retrospective or historical data. The aim of this study was to assess the variation of recurrence risk estimates across calendar periods, WHO classification editions, geographical settings, and healthcare systems.thetermine METHODS: We analyzed 4,111 patients with primary WHO-1/-2 meningiomas from 31 centers in 15 countries (1990-2019). Recurrence was defined according to local radiological assessment. The 5- and 10-year recurrence risks were estimated using regression standardization with inverse probability of censoring weights, adjusting for key clinical, surgical, and histopathological variables. RESULTS: Recurrence risk estimates varied across all domains examined. More recent calendar periods were associated with higher predicted recurrence risk, particularly for WHO-2 at 5 years (e.g., ≥ 2013 vs. ≤ 2007: RR 1.60, 95% CI 1.19-2.01). Differences were also observed across healthcare systems and geographical settings despite adjustment. In contrast, recurrence risk estimates were broadly comparable between WHO classification editions (2007 vs. 2016). Cohort-level visualization revealed substantial heterogeneity in follow-up duration, inclusion patterns, and recurrence detection. CONCLUSIONS: Recurrence risk estimates are not stable across time or settings and are influenced by several patterns, particularly data accrual patterns. Recurrence events are inherently "locked" to the historical context in which they were detected, which may have important implications for developing molecular classifiers using retrospective specimens and clinical trials relying on benchmark established in historical settings. We propose transparent visualization of observational cohort composition and individual-level event timing to improve interpretability and comparability.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Mirian C, Jensen LR, Hoffmann AG, et al. Variation in meningioma recurrence risk estimates across observational cohorts: the influence of calendar time, WHO classifications, geographical settings, and healthcare systems. J Neurooncol. 2026. PMID: 42663731. doi:10.1007/s11060-026-05753-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。